aluates Reports

$ 0.0

Automative

Global Neuromyelitis Optica Drug Market Research Report 2026

Published Date: 2026-01-15

Report Code: QYRE-Auto-16A2404

Global Neuromyelitis Optica Drug Market Insights and Forecast to 2028

BUY CHAPTERS

Global Neuromyelitis Optica Drug Market Research Report 2026

Code: QYRE-Auto-16A2404

Report

2026-01-15

Pages:119

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

Fresenius

TEVA

Sandoz Inc

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL Limited

Grifols S A

Octapharma AG

CBOP

Neuromyelitis Optica Drug Market Size

The global Neuromyelitis Optica Drug market was valued at US$ 51.19 million in 2025 and is anticipated to reach US$ 62.77 million by 2032, at a CAGR of 3.0% from 2026 to 2032.

Neuromyelitis Optica Drug Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.

Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.

This report delivers a comprehensive overview of the global Neuromyelitis Optica Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuromyelitis Optica Drug. The Neuromyelitis Optica Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Neuromyelitis Optica Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Neuromyelitis Optica Drug Market Report

Report Metric	Details
Report Name	Neuromyelitis Optica Drug Market
Accounted market size in 2025	US$ 51.19 million
Forecasted market size in 2032	US$ 62.77 million
CAGR	3.0%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Glucocorticoids Immunotherapies Others
Segment by Application	Acute Attack Remission Prophylactic Treatment
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Neuromyelitis Optica Drug companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Neuromyelitis Optica Drug Market growing?

Ans: The Neuromyelitis Optica Drug Market witnessing a CAGR of 3.0% during the forecast period 2026-2032.

What is the Neuromyelitis Optica Drug Market size in 2032?

Ans: The Neuromyelitis Optica Drug Market size in 2032 will be US$ 62.77 million.

Who are the main players in the Neuromyelitis Optica Drug Market report?

Ans: The main players in the Neuromyelitis Optica Drug Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Applications covered in the Neuromyelitis Optica Drug Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Types covered in the Neuromyelitis Optica Drug Market report are Glucocorticoids, Immunotherapies, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Glucocorticoids

1.2.3 Immunotherapies

1.2.4 Others

1.3 Market by Application

1.3.1 Global Neuromyelitis Optica Drug Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Acute Attack

1.3.3 Remission Prophylactic Treatment

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuromyelitis Optica Drug Market Perspective (2021–2032)

2.2 Global Neuromyelitis Optica Drug Growth Trends by Region

2.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2021–2026)

2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2027–2032)

2.3 Neuromyelitis Optica Drug Market Dynamics

2.3.1 Neuromyelitis Optica Drug Industry Trends

2.3.2 Neuromyelitis Optica Drug Market Drivers

2.3.3 Neuromyelitis Optica Drug Market Challenges

2.3.4 Neuromyelitis Optica Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuromyelitis Optica Drug Players by Revenue

3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2021–2026)

3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2021–2026)

3.2 Global Top Neuromyelitis Optica Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Neuromyelitis Optica Drug Revenue

3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio

3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2025

3.5 Global Key Players of Neuromyelitis Optica Drug Head Offices and Areas Served

3.6 Global Key Players of Neuromyelitis Optica Drug, Products and Applications

3.7 Global Key Players of Neuromyelitis Optica Drug, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Neuromyelitis Optica Drug Breakdown Data by Type

4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2021–2026)

4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2027–2032)

5 Neuromyelitis Optica Drug Breakdown Data by Application

5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2021–2026)

5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Neuromyelitis Optica Drug Market Size (2021–2032)

6.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Neuromyelitis Optica Drug Market Size by Country (2021–2026)

6.4 North America Neuromyelitis Optica Drug Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuromyelitis Optica Drug Market Size (2021–2032)

7.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Neuromyelitis Optica Drug Market Size by Country (2021–2026)

7.4 Europe Neuromyelitis Optica Drug Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2021–2032)

8.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2021–2026)

8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Neuromyelitis Optica Drug Market Size (2021–2032)

9.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2021–2026)

9.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2021–2032)

10.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021–2026)

10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuromyelitis Optica Drug Introduction

11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.1.5 Pfizer Recent Development

11.2 Fresenius

11.2.1 Fresenius Company Details

11.2.2 Fresenius Business Overview

11.2.3 Fresenius Neuromyelitis Optica Drug Introduction

11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.2.5 Fresenius Recent Development

11.3 Teva

11.3.1 Teva Company Details

11.3.2 Teva Business Overview

11.3.3 Teva Neuromyelitis Optica Drug Introduction

11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.3.5 Teva Recent Development

11.4 Sandoz

11.4.1 Sandoz Company Details

11.4.2 Sandoz Business Overview

11.4.3 Sandoz Neuromyelitis Optica Drug Introduction

11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.4.5 Sandoz Recent Development

11.5 Intas

11.5.1 Intas Company Details

11.5.2 Intas Business Overview

11.5.3 Intas Neuromyelitis Optica Drug Introduction

11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.5.5 Intas Recent Development

11.6 Gyjtrs

11.6.1 Gyjtrs Company Details

11.6.2 Gyjtrs Business Overview

11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction

11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.6.5 Gyjtrs Recent Development

11.7 NANG KUANG

11.7.1 NANG KUANG Company Details

11.7.2 NANG KUANG Business Overview

11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction

11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.7.5 NANG KUANG Recent Development

11.8 Tianjin Kingyork

11.8.1 Tianjin Kingyork Company Details

11.8.2 Tianjin Kingyork Business Overview

11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction

11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.8.5 Tianjin Kingyork Recent Development

11.9 Baxter

11.9.1 Baxter Company Details

11.9.2 Baxter Business Overview

11.9.3 Baxter Neuromyelitis Optica Drug Introduction

11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.9.5 Baxter Recent Development

11.10 CSL

11.10.1 CSL Company Details

11.10.2 CSL Business Overview

11.10.3 CSL Neuromyelitis Optica Drug Introduction

11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.10.5 CSL Recent Development

11.11 Grifols

11.11.1 Grifols Company Details

11.11.2 Grifols Business Overview

11.11.3 Grifols Neuromyelitis Optica Drug Introduction

11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.11.5 Grifols Recent Development

11.12 Octapharma

11.12.1 Octapharma Company Details

11.12.2 Octapharma Business Overview

11.12.3 Octapharma Neuromyelitis Optica Drug Introduction

11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.12.5 Octapharma Recent Development

11.13 CBOP

11.13.1 CBOP Company Details

11.13.2 CBOP Business Overview

11.13.3 CBOP Neuromyelitis Optica Drug Introduction

11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2021–2026)

11.13.5 CBOP Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Fresenius

TEVA

Sandoz Inc

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL Limited

Grifols S A

Octapharma AG

CBOP

List of Tables

Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Glucocorticoids

Table 3. Key Players of Immunotherapies

Table 4. Key Players of Others

Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million), 2021–2026

Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2021–2026)

Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2027–2032)

Table 11. Neuromyelitis Optica Drug Market Trends

Table 12. Neuromyelitis Optica Drug Market Drivers

Table 13. Neuromyelitis Optica Drug Market Challenges

Table 14. Neuromyelitis Optica Drug Market Restraints

Table 15. Global Neuromyelitis Optica Drug Revenue by Players (US$ Million), 2021–2026

Table 16. Global Neuromyelitis Optica Drug Market Share by Players (2021–2026)

Table 17. Global Top Neuromyelitis Optica Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Neuromyelitis Optica Drug Revenue, 2025

Table 18. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served

Table 21. Global Key Players of Neuromyelitis Optica Drug, Products and Applications

Table 22. Global Key Players of Neuromyelitis Optica Drug, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global Neuromyelitis Optica Drug Market Size by Type (US$ Million), 2021–2026

Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021–2026)

Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2027–2032)

Table 28. Global Neuromyelitis Optica Drug Market Size by Application (US$ Million), 2021–2026

Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021–2026)

Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2027–2032)

Table 32. North America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026

Table 34. North America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032

Table 35. Europe Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026

Table 37. Europe Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer Neuromyelitis Optica Drug Product

Table 50. Pfizer Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 51. Pfizer Recent Development

Table 52. Fresenius Company Details

Table 53. Fresenius Business Overview

Table 54. Fresenius Neuromyelitis Optica Drug Product

Table 55. Fresenius Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 56. Fresenius Recent Development

Table 57. Teva Company Details

Table 58. Teva Business Overview

Table 59. Teva Neuromyelitis Optica Drug Product

Table 60. Teva Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 61. Teva Recent Development

Table 62. Sandoz Company Details

Table 63. Sandoz Business Overview

Table 64. Sandoz Neuromyelitis Optica Drug Product

Table 65. Sandoz Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 66. Sandoz Recent Development

Table 67. Intas Company Details

Table 68. Intas Business Overview

Table 69. Intas Neuromyelitis Optica Drug Product

Table 70. Intas Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 71. Intas Recent Development

Table 72. Gyjtrs Company Details

Table 73. Gyjtrs Business Overview

Table 74. Gyjtrs Neuromyelitis Optica Drug Product

Table 75. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 76. Gyjtrs Recent Development

Table 77. NANG KUANG Company Details

Table 78. NANG KUANG Business Overview

Table 79. NANG KUANG Neuromyelitis Optica Drug Product

Table 80. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 81. NANG KUANG Recent Development

Table 82. Tianjin Kingyork Company Details

Table 83. Tianjin Kingyork Business Overview

Table 84. Tianjin Kingyork Neuromyelitis Optica Drug Product

Table 85. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 86. Tianjin Kingyork Recent Development

Table 87. Baxter Company Details

Table 88. Baxter Business Overview

Table 89. Baxter Neuromyelitis Optica Drug Product

Table 90. Baxter Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 91. Baxter Recent Development

Table 92. CSL Company Details

Table 93. CSL Business Overview

Table 94. CSL Neuromyelitis Optica Drug Product

Table 95. CSL Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 96. CSL Recent Development

Table 97. Grifols Company Details

Table 98. Grifols Business Overview

Table 99. Grifols Neuromyelitis Optica Drug Product

Table 100. Grifols Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 101. Grifols Recent Development

Table 102. Octapharma Company Details

Table 103. Octapharma Business Overview

Table 104. Octapharma Neuromyelitis Optica Drug Product

Table 105. Octapharma Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 106. Octapharma Recent Development

Table 107. CBOP Company Details

Table 108. CBOP Business Overview

Table 109. CBOP Neuromyelitis Optica Drug Product

Table 110. CBOP Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026

Table 111. CBOP Recent Development

Table 112. Research Programs/Design for This Report

Table 113. Key Data Information from Secondary Sources

Table 114. Key Data Information from Primary Sources

Table 115. Authors List of This Report

List of Figures

Figure 1. Neuromyelitis Optica Drug Picture

Figure 2. Global Neuromyelitis Optica Drug Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Neuromyelitis Optica Drug Market Share by Type: 2025 vs 2032

Figure 4. Glucocorticoids Features

Figure 5. Immunotherapies Features

Figure 6. Others Features

Figure 7. Global Neuromyelitis Optica Drug Market Size by Application (US$ Million), 2021–2032

Figure 8. Global Neuromyelitis Optica Drug Market Share by Application: 2025 vs 2032

Figure 9. Acute Attack Case Studies

Figure 10. Remission Prophylactic Treatment Case Studies

Figure 11. Neuromyelitis Optica Drug Report Years Considered

Figure 12. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 13. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Neuromyelitis Optica Drug Market Share by Region: 2025 vs 2032

Figure 15. Global Neuromyelitis Optica Drug Market Share by Players in 2025

Figure 16. Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2025

Figure 18. North America Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 19. North America Neuromyelitis Optica Drug Market Share by Country (2021–2032)

Figure 20. United States Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. Canada Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Europe Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Neuromyelitis Optica Drug Market Share by Country (2021–2032)

Figure 24. Germany Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. France Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Italy Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Russia Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Ireland Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Neuromyelitis Optica Drug Market Share by Region (2021–2032)

Figure 32. China Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Japan Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. India Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Australia & New Zealand Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Latin America Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Neuromyelitis Optica Drug Market Share by Country (2021–2032)

Figure 40. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Middle East & Africa Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2021–2032)

Figure 44. Israel Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. UAE Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 48. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 49. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 50. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 51. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 52. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 53. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 54. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 55. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 56. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 57. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 58. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 59. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Neuromyelitis Optica Spectrum Disorders NMOSD Market Research Report 2024

Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Research Report 2024

Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights Forecast to 2030

Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Multiple Sclerosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030

Global Optic Neuritis Drug Market Research Report 2025

Global Demyelinating Diseases Therapeutics Market Research Report 2024

Transverse Myelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ischemic Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neuromyelitis Optica Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Neuromyelitis Optica Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Transverse Myelitis Diagonosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Metachromatic Leukodystrophy Treatment Market Research Report 2025

Global Open Angle Glaucoma Therapeutics Market Insights Forecast to 2030

Global Optic Nerve Disorders Treatment Market Insights Forecast to 2030

Optic Neuropathy Management Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Central Nervous System CNS Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions